GTx (GTXI) submits a complete response letter to the FDA regarding the full clinical hold on...

|By:, SA News Editor

GTx (GTXI) submits a complete response letter to the FDA regarding the full clinical hold on prostate cancer treatment Capesaris. The company says it plans to develop Capesaris as a secondary hormonal therapy for advanced prostate cancer at doses lower than those previously tested.